Chc Healthcare Group · TWSE:4164

Chc Healthcare — Investor Presentation (November 2025)

38 slides from Chc Healthcare's investor presentation, Nov 25, 2025

1. Slide 1: CHC Healthcare Group (4164) 2025 Investor Presentation

   7K Se F Be (4164) 2025 FER REARAS CSC axe

2. Slide 2: Disclaimer

   CSC z#+8 WHR AARE RR ARI AIRASI (LA PR REE Pitt > AICPA Bate RGUSRSEXSA > AREBHBSRA CSAS IEE + SHEE +s OER IEE > PEAT AR BAT -ZESPAERHE TR ° AXMPASRA EMEA CARAS > MRLBRMRERREBARA > Pins AAVA HRA > SORA ERAS HRA AA PM ERS BEE © ASSCHP RD AEE eS UME RR > Slee BAIR AS PAA ee BS SI AOR Ee SES RD + SPER

3. Slide 3: Agenda

   CNC a#t8

4. Slide 4: Company overview

   CNC a#t8

5. Slide 5: Company profile

   • • 4164 • 2009 11 27 ( 1977 ) • • • • • 1,953,109,890 • 2012 10 24

6. Slide 6: Company history

   CNC a#t8 eat HERS 70S EB ETERS JARS ake RERERAD RABE 201755 199755 197755. SADR Sa SPUlaHe SS BER SAr< UBS SRR HRSWER EERIE A tH BI SF HX OR ES SE HE i i HK CLUS SRAM K RSIS SE SHAGEEE - ERISA - RASA AS SAO MTR HAR SOS AWA Hee aS Peae Elekta {ugree eae (oO) RAR I

7. Slide 7: Business model

   CSC ae28 Ete 7 hd BAH EARS ED RRAR SE aici)

8. Slide 8: Brand partners

   CNC a#t8 BS] Bem A a Tas ne fh A SP Maes HARES A ARF} ES 4 — re s G 3 aoa AIA EBER “a @ MICROSYSTEMS BRON vcs * BVI Piw IMRIS VUno Bd «<PAstiland -ROWNJUN ELEKTA Comp: ALBOMED ” ECOLAB CAScINATIONS Eanes Qereererne “plasmapp (Bmicrorex = HYC-RAD Klarity [Ec ) Swissray"=* Weis medica

9. Slide 9: Business strategy

   CNC ae28 BAU ARS Bate eS She RA Ate BSR ae ERAS DEAR a FS fH PR Aa LRM — well _ —_—

10. Slide 10: Operating sites

    CSC a##8 SACS Eke - ERR wiaw & “2 j 2 “— Bes - Ed eave ng Pha ale r \ = A ee 4 i. gr t a” K y 3 Twa : BAH a/R - Deru meRRR == cs 4 re \ aa map OS anther = ey a i oo aco

11. Slide 11: Sustainability

    CSC a##8 we Ay cr HE al eH ial Bs] ma Se SUSTAINABILITY Ty) 30% of energy savings | BER

12. Slide 12: Financial results

    CNC a#t8

13. Slide 13: Revenue

    ( ) 5,000,000 3,877,137 4,000,000 3,600,574 3,526,586 2,974,352 2,816,643 3,000,000 2,554,911 2,439,564 2,000,000 1,000,000 - 2020 2021 2022 2023 2024 2024 1~10 2025 1~10 ( ) ( )

14. Slide 14: Financial performance

    CNC a#t8 ORE OBER 9 MBA

15. Slide 15: EBITDA

    ( ) EBITDA ( ) 1,500,000 5 1,231,233 1,200,000 4 970,340 1,001,839 1,042,109 944,553 900,000 3 2.53 2.43 2.55 741,397 2.21 674,175 600,000 2 1.01 300,000 0.74 0.64 1 0 0 362,912 380,282 388,650 425,238 182,577 120,511 120,132 2020 2021 2022 2023 2024 2024 2025

16. Slide 16: Dividends

    ( ) 2.5 160% 140% ( ) ( ) 2 120% 2020 2.01 2.53 79% 1.5 100% 2021 2.011 2.43 83% 80% 1 60% 2022 2.01 2.21 91% 2023 2.01 2.55 79% 40% 0.5 150% 20% 2024 1.51 1.01 0 0% 2020 2021 2022 2023 2024

17. Slide 17: Business segments

    CNC a#t8

18. Slide 18: Elekta Versa HD & Harmony

    CSC RR Ht tA S23B - Versa HD® & Harmony @Elekta —

19. Slide 19: Elekta Evo

    - Elekta Evo Adapt at your rhythm The only CT-Linac that uniquely evolves on your terms and offers everything from the everyday to the extraordinary.

20. Slide 20: Elekta Unity

    CSC a##8 pat HE ts Eee - Elekta (2th Be Ae DE BS Opes So) Elekta Elekta Unity

21. Slide 21: IBA proton therapy

    - IBA 45+% MARKET SHARE 80+ PROTON CENTERS 140,000+ PATIENTS IN PROTON THERAPY POWERED BY IBA TREATED ON IBA EQUIPMENT

22. Slide 22: Baxter

    CNC a#t8 ERR ER - BaxteriE XA FiRRAR Baxter es |i (IVIL T (TU TTUHTTTT TTT]

23. Slide 23: Leica 3D surgical microscope

    – Leica 3D ARveo 8x Hybrid 3D Surgical Microscope

24. Slide 24: BVI ophthalmic surgical devices

    CSC a##8 (Ein em - BVI= EAE TERICA Lk Gas se BVI @evi y FINEVISION HP @ OL ) | GFY @evi Market Leading Portfolio of FReySON aie Ophthalmic Surgical Devices

25. Slide 25: Market trend

    CNC aet8 ha fe RES - IAS Hisihhe A 100 Ed = Raves 80 a PE a 60 o =o) a8 40 » 20 pases BB AE reurie bined OSOSOO ° —— —_ _e res mae» 2008 2012% 2016 2020 #2024 had : Sot: Oe e

26. Slide 26: Irradiation services

    CSC a##8 fhmARRER - BHR HiBieR O neae SRS RH MTIE + ie a WAKE

27. Slide 27: Irradiation process steps

    CNC a#t8 ae aR PAS Se STEP STEP STEP 01 02 03 04 05 06 07 Pepe rd sen © sane @Q@ ore Q@ exec QO we @® seu @® enue (E-Beam & X-Ray) .-..) = — ig. [} =e wA ee a” 2 STEP ‘STEP ‘STEP ‘STEP STEP STEP STEP 01 02 03 04 05 06 07 =] &% 5 ape oes > ~ > | nx > & > |=} > > 1@ RS GS tm > |G Ep ? 0 Sa Ramee Wet E

28. Slide 28: Application areas

    • 消滅微生物 • 消滅細菌 • 抑制食材發芽 食材 醫療 • 確保無菌 • 降低感染風險 • 延長食品保鮮期 應用 領域 • 半導體切換效率提升 • 輻射交聯聚合物 • 材料改性 材料 其他 • 航太材料耐受性測試 • 寶石顏色增強 • 強化複合材料 • 郵政郵件淨化…

29. Slide 29: New business

    CNC a#t8

30. Slide 30: Growth initiatives

    ARES RARER ARR {a 4 R ae 8

31. Slide 31: BNCT strategy

    CSC a##8 sma CHC a here | PAN ths AVVAVANVATINE: ie

32. Slide 32: Neutron Therapeutics

    CSC a##8 5 | EWA HRIEIS I - Neutron Therapeutics *% neutron ‘€therapeutics

33. Slide 33: Neutron Therapeutics technology

    - Neutron Therapeutics • 2.6 MeV 靜電式質子加速器 • 典型運轉電流：30 mA（高通量，中子通量高，提升治療量） • 旋轉式固體鋰靶：將質子束打在固體鋰靶上產生中子、壽命長、可自動維護

34. Slide 34: Neutron Therapeutics comparison

    - Neutron Therapeutics Neutron Therapeutics Sumitomo Dawon Medax 2.6 MeV 30 MeV 10 MeV 30 MeV 30 mA (max 40 mA) 1 mA 2 mA 1 mA 78 kW (max 104 kW) 30 kW 20 kW 30 kW RFQ IGRT (CT guide) V X X X CE X X X 3 2 0 1 V V V X

35. Slide 35: BNCT at HUS

    - Neutron Therapeutics BNCT • 2025/5/16 (HUS) Neutron Therapeutics • Neutron Therapeutics nuBeam® BNCT HUS • HUS 1992 BNCT 200 nuBeam® BNCT

36. Slide 36: nuBeam Suite

    - Neutron Therapeutics 10 Phase 1 • • The nuBeam Suite + The nuBeam Suite   ( CT )   ( RayStation TPS )

37. Slide 37: Neutron Therapeutics installations and partners

    - Neutron Therapeutics Neutron Therapeutics • (SKGH) nuBeam® SKGH • Aviko Radiopharmaceuticals / Leo Cancer Care 2023 Aviko BNCT Leo Cancer Care BNCT • (University of Birmingham) nuBeam® BNCT

38. Slide 38: Thank you!

    Thank you! www.chcg.com Copyright © 2019 CHC Limited. All rights reserved.

CHC Healthcare Group — Investor Presentation (November 2025) on 6ix